Clinical Review of Incretin Based Therapies: Their Role in the Management of Type 2 Diabetes Mellitus Public Deposited

Downloadable Content

Download PDF
Last Modified
  • February 26, 2019
  • Barajas-Graham, Eulalia
    • Affiliation: School of Medicine, Department of Allied Health Sciences, Physician Assistant Program
  • Type 2 Diabetes has become an epidemic in the United States; a disease that according to the CDC, in 2013, was the 7th leading cause of death among Americans. Even though there are various treatments available, it is not very clear when these agents are appropriate for individuals. Some agents have unfavorable side effects and can cause hypoglycemia. Newer agents, incretin based therapies, offer an alternative to controlling hyperglycemia. These agents not only help lower Hemoglobin A1C (HbA1C) values, but they also have the added benefits of weight loss, blood pressure control, and very low risks of hypoglycemia. There are two classes of incretin based therapies, GLP-1 Agonists and DPP-4 Inhibitors. Though these treatments have been on the market for several years, the use and knowledge of these drugs is still not prevalent. This review will discuss the role of incretins in diabetes treatment, the unique benefits these agents offer, their therapeutic efficacy, safety, side effects and reasons why these agents are not being utilized.
Date of publication
Resource type
Rights statement
  • In Copyright
  • Beal, Meg
  • Faurot, Keturah
  • Master of Health Science
Degree granting institution
  • University of North Carolina at Chapel Hill
Graduation year
  • 2017
Deposit record
  • 03017bbf-d2c5-4c32-b5ff-fb580cd5f16e

This work has no parents.